[{"id":"ca3a54db-282a-47be-8c84-13cb7993c8f0","acronym":"GALAXY 3","url":"https://clinicaltrials.gov/study/NCT06926790","created_at":"2025-09-06T17:47:54.931Z","updated_at":"2025-09-06T17:47:54.931Z","phase":"Phase 2","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)","source_id_and_acronym":"NCT06926790 - GALAXY 3","lead_sponsor":"The First Affiliated Hospital of Guangzhou Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 02/17/2025","start_date":" 02/17/2025","primary_txt":" Primary completion: 03/31/2030","primary_completion_date":" 03/31/2030","study_txt":" Completion: 10/31/2030","study_completion_date":" 10/31/2030","last_update_posted":"2025-04-22"},{"id":"0275af4d-adea-470c-80d3-2b61aa1c8803","acronym":"","url":"https://clinicaltrials.gov/study/NCT01950390","created_at":"2021-01-18T08:50:38.167Z","updated_at":"2025-02-25T12:26:04.772Z","phase":"Phase 2","brief_title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01950390","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • CS1002 (ipilimumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 01/24/2014","start_date":" 01/24/2014","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"23898e8b-63ed-4913-ab7c-2d5d7699806b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339571","created_at":"2021-01-18T11:07:01.092Z","updated_at":"2025-02-25T12:26:15.021Z","phase":"Phase 2/3","brief_title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","source_id_and_acronym":"NCT02339571","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 11/23/2015","start_date":" 11/23/2015","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2025-02-24"},{"id":"413aa90a-43b5-4d96-b8cc-5aee512ef199","acronym":"NRG-GY003","url":"https://clinicaltrials.gov/study/NCT02498600","created_at":"2021-01-18T12:02:53.906Z","updated_at":"2025-02-25T12:26:21.840Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02498600 - NRG-GY003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 09/05/2018","primary_completion_date":" 09/05/2018","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"b57cb3c0-4fb2-4fdc-add3-151c7aaf3f51","acronym":"SAINT","url":"https://clinicaltrials.gov/study/NCT03138161","created_at":"2024-04-18T20:51:31.500Z","updated_at":"2025-02-25T12:26:41.043Z","phase":"Phase 1/2","brief_title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT03138161 - SAINT","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 07/31/2031","study_completion_date":" 07/31/2031","last_update_posted":"2025-02-24"},{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"23ac8e6c-a9b5-4a23-995c-206f44787ba3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890329","created_at":"2021-01-18T14:11:09.765Z","updated_at":"2025-02-25T13:48:17.623Z","phase":"Phase 1","brief_title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT02890329","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" High ALC","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e High ALC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 08/19/2025","study_completion_date":" 08/19/2025","last_update_posted":"2025-02-21"},{"id":"a8eb30bd-0fe3-47c6-8e1f-dbc91b74bace","acronym":"ARCITECT","url":"https://clinicaltrials.gov/study/NCT05928806","created_at":"2023-07-03T16:10:37.286Z","updated_at":"2025-02-25T13:41:35.328Z","phase":"Phase 2","brief_title":"Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial","source_id_and_acronym":"NCT05928806 - ARCITECT","lead_sponsor":"Michael B. Atkins, MD","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 10/10/2025","primary_completion_date":" 10/10/2025","study_txt":" Completion: 10/12/2026","study_completion_date":" 10/12/2026","last_update_posted":"2025-02-21"},{"id":"be73eee7-8633-483e-a581-812fd81e01b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929041","created_at":"2021-06-18T23:52:29.992Z","updated_at":"2025-02-25T14:02:22.824Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","source_id_and_acronym":"NCT04929041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 427","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"ed7e0a8d-7121-41ed-982b-5af9f5bc5b3a","acronym":"NRG-GY025","url":"https://clinicaltrials.gov/study/NCT05112601","created_at":"2021-11-09T20:21:18.547Z","updated_at":"2025-02-25T14:16:28.432Z","phase":"Phase 2","brief_title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT05112601 - NRG-GY025","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-18"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"2487ddb2-7738-4021-b64c-94036379e85b","acronym":"CHAMP","url":"https://clinicaltrials.gov/study/NCT04709276","created_at":"2021-01-19T20:52:08.240Z","updated_at":"2025-02-25T14:29:51.192Z","phase":"Phase 2","brief_title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04709276 - CHAMP","lead_sponsor":"Andrew J. Armstrong, MD","biomarkers":" TP53 • PTEN • RB1 • SYP","pipe":" | ","alterations":" LDH elevation","tags":["TP53 • PTEN • RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-14"},{"id":"9c0791f2-df06-44ae-99f3-11a3ceff187a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496208","created_at":"2021-01-18T12:02:15.721Z","updated_at":"2025-02-25T15:10:16.692Z","phase":"Phase 1","brief_title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","source_id_and_acronym":"NCT02496208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/22/2015","start_date":" 07/22/2015","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"9b2dd962-db93-43b8-b077-57bd460b2d26","acronym":"","url":"https://clinicaltrials.gov/study/NCT04996823","created_at":"2021-08-09T13:53:12.104Z","updated_at":"2025-02-25T15:19:13.745Z","phase":"Phase 2","brief_title":"Axitinib + Ipilimumab in Advanced Melanoma","source_id_and_acronym":"NCT04996823","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 03/29/2026","primary_completion_date":" 03/29/2026","study_txt":" Completion: 03/29/2027","study_completion_date":" 03/29/2027","last_update_posted":"2025-02-12"},{"id":"d4207de7-4d28-4ffe-a877-c2adf5f87729","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904080","created_at":"2023-06-15T18:09:01.233Z","updated_at":"2025-02-25T15:28:06.715Z","phase":"Phase 2","brief_title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","source_id_and_acronym":"NCT05904080","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/19/2024","start_date":" 02/19/2024","primary_txt":" Primary completion: 06/16/2028","primary_completion_date":" 06/16/2028","study_txt":" Completion: 06/16/2028","study_completion_date":" 06/16/2028","last_update_posted":"2025-02-12"},{"id":"81c78433-c4cf-4a3b-9d94-ce29fffcad16","acronym":"","url":"https://clinicaltrials.gov/study/NCT01701674","created_at":"2021-01-18T07:24:05.712Z","updated_at":"2025-02-25T14:33:43.754Z","phase":"","brief_title":"Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts","source_id_and_acronym":"NCT01701674","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 10/09/2012","start_date":" 10/09/2012","primary_txt":" Primary completion: 04/21/2016","primary_completion_date":" 04/21/2016","study_txt":" Completion: 09/08/2025","study_completion_date":" 09/08/2025","last_update_posted":"2025-02-10"},{"id":"b172bb8d-07dd-4d40-b459-cb7946457b73","acronym":"NRG-BN007","url":"https://clinicaltrials.gov/study/NCT04396860","created_at":"2021-01-18T21:13:04.295Z","updated_at":"2025-02-25T15:34:40.901Z","phase":"Phase 2/3","brief_title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT04396860 - NRG-BN007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • IDH1 • MGMT","pipe":" | ","alterations":" PD-L1 expression • MGMT promoter methylation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MGMT promoter methylation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 04/13/2023","primary_completion_date":" 04/13/2023","study_txt":" Completion: 03/11/2025","study_completion_date":" 03/11/2025","last_update_posted":"2025-02-10"},{"id":"79725e7c-a938-4a9e-b556-bf960936b158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03618641","created_at":"2021-09-17T01:53:43.496Z","updated_at":"2025-02-25T16:31:32.025Z","phase":"Phase 2","brief_title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","source_id_and_acronym":"NCT03618641","lead_sponsor":"Diwakar Davar","biomarkers":" CD8 • CD4 • SOX10","pipe":"","alterations":" ","tags":["CD8 • CD4 • SOX10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/08/2018","start_date":" 08/08/2018","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-07"},{"id":"2119d121-8980-4c19-8bce-e35f258e6e89","acronym":"EA2201","url":"https://clinicaltrials.gov/study/NCT04751370","created_at":"2021-02-12T13:55:42.607Z","updated_at":"2025-02-25T16:38:15.444Z","phase":"Phase 2","brief_title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT04751370 - EA2201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 02/08/2022","start_date":" 02/08/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"56dc1b56-646f-4648-9e26-4b51bc644b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04317105","created_at":"2021-01-18T20:55:21.759Z","updated_at":"2025-02-25T16:37:48.003Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","source_id_and_acronym":"NCT04317105","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PD-L1 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"6fa362b2-89c2-4884-87bd-ac57c53e5ca0","acronym":"E4412","url":"https://clinicaltrials.gov/study/NCT01896999","created_at":"2021-01-29T07:05:03.634Z","updated_at":"2025-02-25T16:36:17.132Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT01896999 - E4412","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1 • CD4 • LGALS1 • ICOS","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • CD4 • LGALS1 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"b94d473a-a828-47ba-9b4c-363678434e70","acronym":"PDIGREE","url":"https://clinicaltrials.gov/study/NCT03793166","created_at":"2021-01-18T18:45:15.236Z","updated_at":"2025-02-25T16:44:31.244Z","phase":"Phase 3","brief_title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","source_id_and_acronym":"NCT03793166 - PDIGREE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1175","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 09/15/2025","primary_completion_date":" 09/15/2025","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2025-02-06"}]